FDA Approves Larotrectinib for NTRK+ Cancers

November 26, 2018 – The FDA has granted an accelerated approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. The approval is based on findings from patients with TRK-positive … (leggi tutto)